Use of hard gelatin capsules and sodium alginates in peroral prolonged-release formulations

http://www.ester.ee/record=b1047152*es

Evaluation of solid dispersed particles for formulation of oral ibuprofen tablets

Dissolution profiles of two commercial products (Motrine and Rufen®) were analyzed and compared at 8 pH levels, ranging from pH 2.0 to pH 8.0. It was demonstrated, as expected, that the rate and extent of ibuprofen dissolution dissolution was pH dependent. In vitro dissolution characteristics of the ibuprofen solid dispersion formulations prepared by freeze-drying method with various proportions of excipients (theobroma oil, lecithin and PEG 20,000) were investigated at 3 pH levels - pH 2.0, 5.4, and 7.2. As the amount of theobroma oil increased from zero to 31%, the dissolution rate and the percent ibuprofen dissolved was decreased. Freeze-dried systems with a combination of lecithin and PEG 20,000 showed a slower dissolution rate and less amount of drug dissolved than the formulation with only PEG 20,000. The optimal ratio of drug to PEG 20,000 was 1:1. Solid dispersions of ibuprofen prepared by the freezedrying method provided the highest dissolution rate and percentage of drug dissolved when compared with the direct melting method, the solvent method or the physical-mixing method. Dissolution characteristics of the ibuprofen freeze-dried formulation (ratio of drug to PEG 20,000 1:1) were unaffected after storage in 98% relative humidity, but commercial formulation dissolution was drastically reduced. Relative bioavailability of ibuprofen solid dispersed tablets were studied in rabbits after a single oral administration of 50 mg ibuprofen preparations. The freeze-dried solid dispersion formulation with ratio of drug to PEG 1:1 exhibited the greatest relative extent of absorption (129.50 +̲ 27.99% over control). Preparations with PEG 20,000 enhanced the extent of absorption when compared to the formulation of ibuprofen drug powder. There appeared no advantage in formulating ibuprofen in PEG by freeze-drying over the direct melting method. A slower rate of absorption of ibuprofen was obtained when the amount of theobroma oil was increased in the formulation

Simple model to explain effects of plasma protein binding and tissue binding on calculated volumes of distribution, apparent elimination rate constants and clearances

A simple pharmacokinetic model, incorporating linear plasma protein binding, linear tissue binding, and first order elimination of free (unbound) drug, was studied. If Cl p is the plasma clearance, V f is the “true” volume of distribution of free drug, β is the apparent elimination rate constant, σ is the fraction of the drug which is free in plasma, f is the fraction of the drug which is free in the entire body, k f is the intrinsic elimination rate constant for free drug, and A TB o is the initial amount of drug which is bound to tissues, then the model indicates that the following relationships hold: (1) Cl p = V f σ k f ; (2) β = f k f ; and V dext = (σ/f) V f . Only σ, and not f, can be measured experimentally . Dividing Cl p by σ provides an estimate of the intrinsic clearance of free drug, V f k f . A plot of V dext versus σ has an intercept equal to V f , and the ratio of the slope/intercept is an estimate of A TB o /A f o , where A f o is the initial amount of free drug (equal to V f times initial concentration of free drug in plasma). Thus, an estimate of A TB o may be obtained. Dividing the intrinsic clearance by V f provides an estimate of k f . Thus, theoretically, estimates of V f , k f , A TB o and f may be obtained. The variables are not separated when β is plotted versus σ, and curvature of such plots is expected; no useful information is obtained from such plots.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/46634/1/228_2004_Article_BF00563079.pd

Characterization of Irradiated Metal Waste from the Pyrometallurgical Treatment of Used EBR-II Fuel

As part of the pyrometallurgical treatment of used Experimental Breeder Reactor-II fuel, a metal waste stream is generated consisting primarily of cladding hulls laden with fission products noble to the electrorefining process. Consolidation by melting at high temperature [1873 K (1600 degrees C)] has been developed to sequester the noble metal fission products (Zr, Mo, Tc, Ru, Rh, Te, and Pd) which remain in the iron-based cladding hulls. Zirconium from the uranium fuel alloy (U-10Zr) is also deposited on the hulls and forms Fe-Zr intermetallics which incorporate the noble metals as well as residual actinides during processing. Hence, Zr has been chosen as the primary indicator for consistency of the metal waste. Recently, the first production-scale metal waste ingot was generated and sampled to monitor Zr content for Fe-Zr intermetallic phase formation and validation of processing conditions. Chemical assay of the metal waste ingot revealed a homogeneous distribution of the noble metal fission products as well as the primary fuel constituents U and Zr. Microstructural characterization of the ingot confirmed the immobilization of the noble metals in the Fe-Zr intermetallic phase

High performance liquid chromatographic analysis of erythromycin in serum and urine

Erythromycin, a macrolide antibiotic used mainly against gram-positive bacteria has been in clinical use since 1952 (1). Previous pharmacokinetic data published on this antibiotic have been derived predominantly from microbiological assay techniques. However, these techniques are relatively imprecise as well as being non-specific and extremely tedious to perform. A novel high performance liquid chromatographic analysis of erythromycin in human serum and urine using U.V. detection at 200 nm and/or electrochemical detection using both an amperometric and a coulometric electrochemical detector is presented. The method involves a solid phase extraction procedure followed by a simple phase separation step and chromatography on a reverse phase column. In order to select the optimum U.V. detector for this analysis, five "state of the art" detectors were compared in terms of their signal-to-noise ratios at U.V. wavelengths between 200 and 210 nm. A known metabolite des-N-methylerythromycin is readily detectable using U.V. detection, whilst another metabolite/degradation product anhydroerythromycin is not seen using U.V. detection but is readily observable using an electrochemical detector. The method has a limit of sensitivity of 0.25 μg/mL and 1.00 μg/mL in serum and urine respectively (U.V. detection) and is sufficiently sensitive to monitor serum and urine concentrations of erythromycin in man after administration of a single 500 mg erythromycin stearate tablet.KMBT_363Adobe Acrobat 9.53 Paper Capture Plug-i

Physiologically based pharmacokinetic modeling of transdermal selegiline and its metabolites for the evaluation of disposition differences between healthy and special populations

A physiologically based pharmacokinetic (PBPK) model of selegiline (SEL), and its metabolites, was developed in silico to evaluate the disposition differences between healthy and special populations. SEL is metabolized to methamphetamine (MAP) and desmethyl selegiline (DMS) by several CYP enzymes. CYP2D6 metabolizes the conversion of MAP to amphetamine (AMP), while CYP2B6 and CYP3A4 predominantly mediate the conversion of DMS to AMP. The overall prediction error in simulated PK, using the developed PBPK model, was within 0.5–1.5-fold after intravenous and transdermal dosing in healthy and elderly populations. Simulation results generated in the special populations demonstrated that a decrease in cardiac output is a potential covariate that affects the SEL exposure in renally impaired (RI) and hepatic impaired (HI) subjects. A decrease in CYP2D6 levels increased the systemic exposure of MAP. DMS exposure increased due to a reduction in the abundance of CYP2B6 and CYP3A4 in RI and HI subjects. In addition, an increase in the exposure of the primary metabolites decreased the exposure of AMP. No significant difference between the adult and adolescent populations, in terms of PK, were observed. The current PBPK model predictions indicate that subjects with HI or RI may require closer clinical monitoring to identify any untoward effects associated with the administration of transdermal SEL patch

Application of high-performance liquid chromatography to the analysis, stability and pharmacokinetics of erythromycin

Erythromycin is a macrolide antibiotic used mainly in the treatment of infections caused by gram-positive organisms. Erythromycin base is rap idly degraded in acidic media necessitating the use of structurally modified erythromycin derivatives or acid resistant dosage forms in order to decrease gastric inactivation of the drug. The majority of pharmacokinetic studies to-date have utilized relatively non-specific microbiological assay procedures which are unable to differentiate between concentrations of active erythromycin base and the inactive pro-drug derivatives. A high-performance liquid chromatographic (HPLC) technique is described for the simultaneous determination of erythromycin base and propionate (inactive pro-drug form) in human serum and urine following the oral administration of erythromycin estolate, an acid stable derivative of erythromycin. The method involves a solid-phase extraction step prior to chromatography on a C18 reversed-phase column with coulometric electrochemical detection. Sample handling and storage techniques are presented which minimize hydrolysis of the inactive ester moiety between sample collection and analysis, thereby more accurately reflecting the in vivo situation than in previously published studies. Results from single dose pharmacokinetic studies indicate that only 10-15% of the total erythromycin concentration in vivo is present as the active base component following oral administration of erythromycin estolate. This percentage increases to approximately 25% during multiple dose administration. Novel urinary excretion data are presented which reveal that approximately 40% and 55% of the total erythromycin excreted in urine is excreted as erythromycin base following single and multiple dosages respectively. Computer fitting of mean serum concentration-time data revealed that an open one compartment model with linear first order absorption and elimination best described the absorption and disposition of erythromycin, although poor computer fits for individual data sets were observed. Some evidence of non-linear elimination is presented utilizing both compartmental and non-compartmental pharmacokinetic techniques. Large intra-and inter-personal variability in erythromycin absorption and disposition was experienced which was evaluated in five subjects who each received one 500 mg erythromycin estolate tablet from the same batch, on three separate occasions. In addition. an HPLC method is described for the analysis of "total erythromycin" concentrations following erythromycin estolate administration which involves hydrolysis of the ester component prior to chromatography. as well as an HPLC method utilizing amperometric electrochemical detection capable of monitoring the stability of erythromycin base in stored biological fluids. These methods were uti I ized in various stability studies involving erythromycin base and propionate as well as for the analysis of erythromycin estolate dosage forms

High-performance liquid chromatographic studies of the acid degradation, pharmacokinetics and comparative bioavailability of erythromycin

Erythromycin is a macrolide antibiotic with a spectrum similar to penicillin and is used mainly in the treatment of infections caused by gram-positive organisms. Since its discovery in 1952, erythromycin has achieved wide-spread clinical use. Susceptibility of erythromycin base to inactivation by acid results in decreased availability following exposure to acidic gastric fluids. Formulation of acid resistant dosage forms and the preparation of acid stable chemical derivatives have been attempted to improve absorption and subsequent clinical efficacy . Two of the most commonly used erythromycin derivatives are the stearic acid salt (erythromycin stearate) and the lauryl sulphate salt of the propionyl ester (erythromycin estolate). Although it has been known for many years that erythromycin is susceptible to acid degradation, very few reports on the stability of erythromycin in aqueous solutions appear in the literature. In this study, a high-performance liquid chromatographic system using electrochemical detection was employed for a kinetic study of erythromycin degradation. The effect of varying acid pH on the degradation rate of both erythromycin base and erythromycin stearate, and the effect on the hydrolysis rate of erythromycin estolate is presented. In addition, the effect of temperature on erythromycin degradation was also investigated. Until recently, the majority of pharmacokinetic and bioavailability studies have utilized relatively non-specific microbiological assay procedures. However, in this study a solid phase extraction, followed by the use of a high-performance liquid chromatographic system using electrochemical coulometric detection was employed for the determination of erythromycin in biological fluids. Human volunteers each received enteric coated erythromycin base pellets in capsule dosage form and also film coated erythromycin stearate tablets on separate occasions. Results from the clinical trials revealed the enteric coated erythromycin base pellets had a greater bioavailability than the film coated erythromycin stearate tablets. Computer fitting of data revealed no intra-volunteer variability in elimination rate constants, suggesting differences in serum levels following administration of both dosage forms are due to variation in absorption. Results from the clinical trials were also compared with those obtained from a further trial, during which the same volunteers received erythromycin estolat

Psychoactive substances as substrates or inhibitors of enzymes in drug metabolism and transport

In contrast to therapeutic drugs, drugs of abuse (DOA) are marketed without (pre)clinical studies. In order to expand the knowledge surrounding toxicokinetics of DOA, the affinity and/or inhibition potential of selected DOA towards human metabolic enzymes such as monooxygenases or monoamine oxidases (MAO) and an efflux transporter, the breast cancer resistance protein (BCRP), was investigated using mass spectrometry techniques. FMO3 was identified as main enzyme involved in the N-oxygenation of N,N-diallyltryptamine and methamphetamine. Furthermore, a broad range of alpha-methyltryptamine-derived new psychoactive substances but also phenethylamines of the 2C-series were identified as MAO inhibitors. Finally, the BCRP ATPase was shown to be potently stimulated or inhibited by 3,4-BDB or WIN 55,212-2, respectively, comparable to model substrates or inhibitors